Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Gilead Sciences: New Data Demonstrate Trodelvy Survival Benefit in Metastatic TNBC. See Also: Galapagos NV News

Gilead Sciences New Data from Trodelvy® Study Gilead Sciences ( GILD ) has recently announced new data from the Phase 3 ASCENT study evaluating Trodelvy® in patients with relapsed or refractory metastatic triple-negative breast cancer ( TNBC ) who received two...

September 17, 2021

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product has been game changer in the treatment of various difficult to treat cancers before the products that target PD-L1 and approved for several various...

August 26, 2023

Why Arcturus Therapeutics Holdings' Pipeline Products are Promising

The information is the first of a few biotech Companies that we believe are promising in treating severe devastating untreatable sicknesses. Arcturus Therapeutics Holdings Based in San Diego, California, Arcturus Therapeutics Holdings ( ARCT ) was founded in 2013. The Company...

December 27, 2023

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label

Sarepta Therapeutics in the NEWS On 12, 22, 2023, Sarepta Therapeutics ( SRPT ) - a precision genetic medicine for rare diseases, announced submission of an efficacy supplement to the Biologics License Application ( BLA ) for ELEVIDYS (delandistrogene moxeparvovec-rokl)...

December 28, 2023

Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

Cytokinetics We recently became enthusiastic about Cytokinetics’ ( CYTK ) current clinical trial results. A few days ago, Cytokinetics announced positive results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3...

December 29, 2023

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences ( ALPN ) announced a successful initiation of the second IgA nephropathy ( IgAN ) dose cohort in RUBY-3, a phase 1b/2a study in autoimmune glomerulonephritis. The safety Monitoring Committee (SMC)...

August 31, 2023

Yes, Compugen's Stock is Soaring, But Why?

Compugen's Soaring Stock Many recent events led to Compugen's ( CGEN ) soaring stock after a huge decline in its price. In spite of the tremendous stock decline, Prohost never doubted the fact that Compugen has solid scientific fundamentals and...

January 2, 2024

The World Health Organization Recommends Regeneron Pharmaceuticals Antibody Cocktail for COVID-19

Regeneron Welcomes the World Health Organization's Recommendation for Use of REGEN- COVTM to Treat COVID-19 The World Health Organization ( WHO ) updated its Therapeutics and COVID-19: living guideline to include the casirivimab and imdevimab monoclonal antibody cocktail, known as...

September 24, 2021

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK ) - a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases...

September 21, 2023

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Soleno Therapeutics ( SLNO ) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome...

September 28, 2023

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024